MBX Biosciences
MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for people living with endocrine and metabolic disorders. Its proprietary Precision Endocrine Peptide (PEP) platform engineers long-acting peptide prodrugs, and its pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, MBX 4291 for obesity, and MBX 5765 for post-bariatric hypoglycemia. The company is publicly traded on Nasdaq under the ticker MBX. As a clinical-stage biotech it publishes no public API, developer portal, SDKs, or technical documentation surface; this profile is maintained for network completeness.
MBX Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Healthcare, and Life Sciences.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API